|View printer-friendly version|
CPV is the most significant and contagious viral cause of enteritis in dogs, especially puppies, with mortality rates reportedly as high as 91% if untreated. There are currently no Food and Drug Administration or United States Department of Agriculture approved treatments for CPV, nor any other available treatment.
"We are very pleased to have entered into this strategic collaboration. Elanco is a recognized leader in animal health with an extensive global commercial footprint and a great reputation for being a partner of choice within the veterinary industry, who shares our commitment to novel, first-in-class therapies for pets," said KindredBio's Chief Executive Officer,
Under the terms of the agreement, KindredBio will receive an upfront payment of
"Elanco is excited to collaborate with KindredBio to advance KIND-030 – a first-in-class monoclonal antibody to address the significant unmet need stemming from canine parvovirus infection," said
With commercial sales and marketing teams located in 48 countries with the ability to reach animals in up to 100 countries, a sales force exceeding 2,000 people and complementary vaccine and therapeutics portfolios, Elanco is strongly positioned to market KIND-030 in
Currently, owners spend up to thousands of dollars per puppy in supportive care for CPV, with average cost of
KIND-030 is being pursued for two indications in dogs: prophylactic therapy to prevent clinical signs of canine parvovirus infection and treatment of established parvovirus infection.
Separately, KindredBio announces that it is on track to start the pivotal efficacy study for tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin-31 for the treatment of atopic dermatitis in dogs by year-end 2020. Furthermore, the pilot field effectiveness study for KindredBio's anti-TNF antibody for canine inflammatory bowel disease is on course to complete and read out by year-end.
For more information, visit: www.kindredbio.com
Learn more at www.elanco.com
This press release contains forward-looking statements within the meaning of the
These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our products and our product candidates for the foreseeable future; the likelihood that our revenue will vary from quarter to quarter; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our products and our lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our products and our product candidates and the potential inability of these manufacturers to deliver a sufficient amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on our business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to enter into satisfactory agreements with third-party licensees of our biologic products or to develop a satisfactory sales organization for our equine small molecule products; our significant costs of operating as a public company; potential cyber-attacks on our information technology systems or on our third-party providers' information technology systems, which could disrupt our operations; our potential inability to repay the secured indebtedness that we have incurred from third-party lenders, and the restrictions on our business activities that are contained in our loan agreement with these lenders; the risk that our 2020 strategic realignment and restructuring plans will result in unanticipated costs or revenue shortfalls; uncertainty about the amount of royalties that we will receive from the sale of Mirataz® to Dechra Pharmaceuticals PLC; the risk that the revenue from our delivery of services or products under any contract may be less than we anticipate if the other party to the contract exercises its right to terminate the contract prior to the completion of the contract; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.
For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the
The results stated in this press release have not been reviewed by the
For investor inquiries:
1 2014 Banfield State of
View original content to download multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-announces-agreement-granting-elanco-exclusive-global-rights-for-its-parvovirus-monoclonal-antibody-301191004.html